April 27, 2017
The Second Circuit on Wednesday reversed a $3.5 million summary judgment in favor of New York University in a breach of contract dispute between the school and drugmaker Galderma Laboratories, finding that the district court had no basis to conclude the rosacea drug Oracea was or wasn't a licensed product.
April 19, 2017
A Second Circuit judge hearing the appeal of a $3.5 million summary judgment in favor of New York University in a breach of contract dispute between the school and drugmaker Galderma Laboratories Inc. told the parties Wednesday that U.S. District Judge Alvin K. Hellerstein made a "crystal clear mistake" of New York law in deciding the case.